euro adhoc: LION bioscience AG / Management Changes / LION bioscience AG expands Management Board after successful acquisition of SYGNIS Bioscience GmbH & Co. KG

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

09.10.2006

Heidelberg, October 9, 2006 - After successful completion of
the capital increase in connection with the acquisition of SYGNIS
Bioscience GmbH & Co. KG, the Supervisory Board of LION bioscience
AG today appointed Dr. Alfred Bach to the Management Board with
effect of October 10, 2006. Up to now Dr. Alfred Bach was CEO of
Axaron Bioscience AG, a drug developing company in the field of CNS
(central nervous system). Dr. Alfred Bach will serve as CEO,
and Peter Willinger as CFO of LION bioscience AG. The acquisition of
all the shares in SYGNIS Bioscience GmbH & Co. KG, as
announced in July 2006, was now successfully completed with
registration in the commercial register. Following the acquisition
of SYGNIS Bioscience GmbH & Co. KG, the share capital of LION
bioscience AG was increased by Euro 7.807.535 from Euro
19.870.175 to Euro 27.677.710. Lion bioscience AG will present
the next steps for future development on the annual
shareholders' meeting for fiscal year 2005/2006 on November 28,
2006 in Eppelheim.

### Except for the historical information contained herein, the
matters set forth in this press release are forward looking. These
forward-looking statements may include projections, assumptions,
estimates, targets, and descriptions of future events. Such
statements are based on currently available information and on
LION's current expectations as to future events that may not prove
to be accurate. These statements are not guarantees of future
performance and involve risks and uncertainties that are difficult
to predict. Many factors could cause the actual results,
performance or achievements of LION to be materially different
from those that may be projected, expected, targeted, expressed
or implied by such statements. All roll-out plans and future dates
with respect to completion of development and market release of LION
products are target dates only based on the company's current
planning and may change in the future. Any delays in the current
product release schedule will have a materially adverse effect on
the company's targets for fiscal year. ###

end of announcement euro adhoc 09.10.2006 17:31:15
--------------------------------------------------------------------------------

ots Originaltext: Lion Bioscience
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Peter Willinger
Vorstand Finanzen
Telefon: +49(0)6221 4038 293
E-Mail: peter.willinger@lionbioscience.com

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
New York / ADR
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade